On March 5, 2019 Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, reported that Gavin Bennett, Ph.D., Bicycle’s Director of Preclinical Development and Project leader for BT5528, will present at the 9th Annual World ADC Conference in London (Press release, Bicycle Therapeutics, MAR 5, 2019, View Source [SID1234533971]). The presentation, focused on Bicycle’s pre-clinical BT5528 program for the treatment of solid tumours, will take place at 11:30 a.m. GMT on Wednesday, March 6.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We expect BT5528 to be Bicycle’s second clinical oncology product candidate and will build on the ongoing Phase I/IIa clinical study with BT1718. We are very excited about its potential to treat solid tumours," said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics. "Preclinical data from our BT5528 program shows target-dependent anti-tumour activity across a range of EphA2-expressing tumour models without evidence of the profound toxicity seen with previous clinical-stage antibody drug conjugates targeting EphA2."
Dr. Bennett has also been invited to chair the "Discovery" track sessions at the conference.